Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575430 · ClinicalTrials.gov registry record
Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT
A clinical trial, sponsored by QLT.
- Completed
- Registry status
- 59
- Enrollment target
NCT02575430: Completed study, sponsored by QLT.
NCT02575430 is a clinical trial that has completed, run by QLT. The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02575430 has completed, sponsored by QLT.
- COMPLETED
- Registry status
- 59 participants
- Enrollment target
Study Summary
To evaluate the natural history of visual function in subjects with IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
Interventions
- OTHER No treatment: retrospective chart review
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-03 |
What the finished NCT02575430 record still lists
NCT02575430 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 59 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which No treatment: retrospective chart review is the first listed.
NCT02575430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02575430 about?
NCT02575430 is a clinical study titled "Natural History Study in Inherited Retinal Disease Subjects Caused by Mutations in RPE65 or LRAT". To evaluate the natural history of visual function in subjects with IRD phenotypically diagnosed as Leber congenital amaurosis (LCA) or retinitis pigmentosa (RP) caused by RPE65 or LRAT gene mutations.
What is the current status of trial NCT02575430?
This trial is currently completed. The enrollment target is 59 participants. The study started on 2015-12. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02575430?
The interventions under investigation include: No treatment: retrospective chart review (OTHER).
Who is sponsoring clinical trial NCT02575430?
This trial is sponsored by QLT, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia